Search

Your search keyword '"MacGowan, Alasdair"' showing total 718 results
Start Over Author "MacGowan, Alasdair"
718 results on '"MacGowan, Alasdair"'

1. Outcomes of octogenarians and nonagenarians with Pseudomonas aeruginosa bacteremia: a multicenter retrospective study

Author

Atamna, Alaa, Margalit, Ili, Ayada, Gida, Babich, Tanya, Naucler, Pontus, Valik, John Karlsson, Giske, Christian G., Benito, Natividad, Cardona, Ruben, Rivera, Alba, Pulcini, Celine, Fattah, Manal Abdel, Haquin, Justine, Macgowan, Alasdair, Chazan, Bibiana, Yanovskay, Anna, Ami, Ronen Ben, Landes, Michal, Nesher, Lior, Zaidman-Shimshovitz, Adi, McCarthy, Kate, Paterson, David L., Tacconelli, Evelina, Buhl, Michael, Mauer, Susanna, Rodríguez-Baño, Jesús, de Cueto, Marina, Oliver, Antonio, de Gopegui, Enrique Ruiz, Cano, Angela, Machuca, Isabel, Gozalo-Marguello, Monica, Martinez-Martinez, Luis, Gonzalez-Barbera, Eva M., Alfaro, Iris Gomez, Salavert, Miguel, Beovic, Bojana, Saje, Andreja, Mueller–Premru, Manica, Pagani, Leonardo, Vitrat, Virginie, Kofteridis, Diamantis, Zacharioudaki, Maria, Maraki, Sofia, Weissman, Yulia, Paul, Mical, Dickstei, Yaakov, and Yahav, Dafna

Published
2023
Full Text
View/download PDF

2. System-wide approaches to antimicrobial therapy and antimicrobial resistance in the UK: the AMR-X framework

Author

Abel, Kathryn, Agnew, Emily, Amos, James, Armstrong, Natalie, Armstrong-James, Darius, Ashfield, Thomas, Aston, Stephen, Baillie, J Kenneth, Baldwin, Steven, Barlow, Gavin, Bartle, Victoria, Bielicki, Julia, Brown, Colin, Carrol, Enitan, Clements, Michelle, Cooke, Graham, Dane, Aaron, Dark, Paul, Day, Jeremy, de-Soyza, Anthony, Dowsey, Andrew, Evans, Stephanie, Eyre, David, Felton, Timothy, Fowler, Tom, Foy, Robbie, Gannon, Karen, Gerada, Alessandro, Goodman, Anna, Harman, Tracy, Hayward, Gail, Holmes, Alison, Hopkins, Susan, Howard, Philip, Howard, Alexander, Hsia, Yingfen, Knight, Gwen, Lemoine, Nick, Koh, James, Macgowan, Alasdair, Marwick, Charis, Moore, Catrin, O’Brien, Seamus, Oppong, Raymond, Peacock, Sharon, Pett, Sarah, Pouwels, Koen, Queree, Chris, Rahman, Najib, Sculpher, Mark, Shallcross, Laura, Sharland, Michael, Singh, Jasvinder, Stoddart, Karen, Thomas-Jones, Emma, Townsend, Andrew, Ustianowski, Andrew, Van Staa, Tjeerd, Walker, Sarah, White, Peter, Wilson, Paul, Buchan, Iain, Woods, Beth, Bower, Peter, Llewelyn, Martin, and Hope, William

Published
2024
Full Text
View/download PDF

3. Oral minocycline plus rifampicin versus oral linezolid for complicated skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus: the AIDA open label, randomized, controlled Phase 4 trial

Author

Kotsaki, Antigone, Tziolos, Nikolaos, Kontopoulou, Theano, Koutelidakis, Ioannis M., Symbardi, Styliani, Reed, Vaughan, O'Hare, Miriam, Alexiou, Zoi, Sambatakou, Helen, Toutouzas, Konstantinos, Akinosoglou, Karolina, Lada, Malvina, Giamarellos-Bourboulis, Evangelos J., and MacGowan, Alasdair

Published
2023
Full Text
View/download PDF

4. Duration of Treatment for Pseudomonas aeruginosa Bacteremia: a Retrospective Study

Author

Babich, Tanya, Naucler, Pontus, Valik, John Karlsson, Giske, Christian G., Benito, Natividad, Cardona, Ruben, Rivera, Alba, Pulcini, Celine, Fattah, Manal Abdel, Haquin, Justine, Macgowan, Alasdair, Grier, Sally, Chazan, Bibiana, Yanovskay, Anna, Ami, Ronen Ben, Landes, Michal, Nesher, Lior, Zaidman-Shimshovitz, Adi, McCarthy, Kate, Paterson, David L., Tacconelli, Evelina, Buhl, Michael, Mauer, Susanna, Rodríguez-Baño, Jesús, de Cueto, Marina, Oliver, Antonio, de Gopegui, Enrique Ruiz, Cano, Angela, Machuca, Isabel, Gozalo-Marguello, Monica, Martinez-Martinez, Luis, Gonzalez-Barbera, Eva M., Alfaro, Iris Gomez, Salavert, Miguel, Beovic, Bojana, Saje, Andreja, Mueller–Premru, Manica, Pagani, Leonardo, Vitrat, Virginie, Kofteridis, Diamantis, Zacharioudaki, Maria, Maraki, Sofia, Weissman, Yulia, Paul, Mical, Dickstein, Yaakov, Leibovici, Leonard, and Yahav, Dafna

Published
2022
Full Text
View/download PDF

9. Therapeutic potential of IL6R blockade for the treatment of sepsis and sepsis-related death: A mendelian randomisation study

Author

Hamilton, Fergus W., Thomas, Matt, Arnold, David, Palmer, Tom, Moran, Ed, Mentzer, Alexander J., Maskell, Nick, Baillie, Kenneth, Summers, Charlotte, Hingorani, Aroon, MacGowan, Alasdair, Khandaker, Golam M., Mitchell, Ruth, Davey Smith, George, Ghazal, Peter, and Timpson, Nicholas J.

Subjects
Interleukin-6 -- Health aspects -- Dosage and administration -- Testing, Sepsis -- Care and treatment -- Patient outcomes, Biological sciences
Abstract

Background Sepsis is characterised by dysregulated, life-threatening immune responses, which are thought to be driven by cytokines such as interleukin 6 (IL-6). Genetic variants in IL6R known to down-regulate IL-6 signalling are associated with improved Coronavirus Disease 2019 (COVID-19) outcomes, a finding later confirmed in randomised trials of IL-6 receptor antagonists (IL6RAs). We hypothesised that blockade of IL6R could also improve outcomes in sepsis. Methods and findings We performed a mendelian randomisation (MR) analysis using single nucleotide polymorphisms (SNPs) in and near IL6R to evaluate the likely causal effects of IL6R blockade on sepsis (primary outcome), sepsis severity, other infections, and COVID-19 (secondary outcomes). We weighted SNPs by their effect on CRP and combined results across them in inverse variance weighted meta-analysis, proxying the effect of IL6RA. Our outcomes were measured in UK Biobank, FinnGen, the COVID-19 Host Genetics Initiative (HGI), and the GenOSept and GainS consortium. We performed several sensitivity analyses to test assumptions of our methods, including utilising variants around CRP and gp130 in a similar analysis. In the UK Biobank cohort (N = 486,484, including 11,643 with sepsis), IL6R blockade was associated with a decreased risk of our primary outcome, sepsis (odds ratio (OR) = 0.80; 95% confidence interval (CI) 0.66 to 0.96, per unit of natural log-transformed CRP decrease). The size of this effect increased with severity, with larger effects on 28-day sepsis mortality (OR = 0.74; 95% CI 0.47 to 1.15); critical care admission with sepsis (OR = 0.48, 95% CI 0.30 to 0.78) and critical care death with sepsis (OR = 0.37, 95% CI 0.14 to 0.98). Similar associations were seen with severe respiratory infection: OR for pneumonia in critical care 0.69 (95% CI 0.49 to 0.97) and for sepsis survival in critical care (OR = 0.22; 95% CI 0.04 to 1.31) in the GainS and GenOSept consortium, although this result had a large degree of imprecision. We also confirm the previously reported protective effect of IL6R blockade on severe COVID-19 (OR = 0.69, 95% CI 0.57 to 0.84) in the COVID-19 HGI, which was of similar magnitude to that seen in sepsis. Sensitivity analyses did not alter our primary results. These results are subject to the limitations and assumptions of MR, which in this case reflects interpretation of these SNP effects as causally acting through blockade of IL6R, and reflect lifetime exposure to IL6R blockade, rather than the effect of therapeutic IL6R blockade. Conclusions IL6R blockade is causally associated with reduced incidence of sepsis. Similar but imprecisely estimated results supported a causal effect also on sepsis related mortality and critical care admission with sepsis. These effects are comparable in size to the effect seen in severe COVID-19, where IL-6 receptor antagonists were shown to improve survival. These data suggest that a randomised trial of IL-6 receptor antagonists in sepsis should be considered., Author(s): Fergus W. Hamilton 1,2,*, Matt Thomas 3, David Arnold 4, Tom Palmer 1, Ed Moran 2, Alexander J. Mentzer 5, Nick Maskell 4, Kenneth Baillie 6, Charlotte Summers 7, [...]

Published
2023
Full Text
View/download PDF

11. Antibiotic pharmacokinetics in infected pleural effusions.

Author

Arnold, David T., Read, Liam, Waddington, Oliver, Hamilton, Fergus W., Patole, Sonia, Hughes, Jessica, Milne, Alice, Noel, Alan, Bayliss, Mark, Maskell, Nicholas A., and MacGowan, Alasdair

Subjects
NUCLEOTIDE sequencing, SCHOLARSHIPS, CO-trimoxazole, HAEMOPHILUS influenzae, ESCHERICHIA coli, CLINDAMYCIN
Published
2024
Full Text
View/download PDF

12. Optimizing the Design and Analysis of Clinical Trials for Antibacterials Against Multidrug-resistant Organisms : A White Paper From COMBACTE’s STAT-Net

Author

COMBACTE-NET Consortium, de Kraker, Marlieke E. A., Sommer, Harriet, de Velde, Femke, Gravestock, Isaac, Weiss, Emmanuel, McAleenan, Alexandra, Nikolakopoulos, Stavros, Amit, Ohad, Ashton, Teri, Beyersmann, Jan, Held, Leonhard, Lovering, Andrew M., MacGowan, Alasdair P., Mouton, Johan W., Timsit, Jean-François, Wilson, David, Wolkewitz, Martin, Bettiol, Esther, Dane, Aaron, and Harbarth, Stephan

Published
2018

20. Antibiotic pharmacokinetics in infected pleural effusions

Author

Arnold, David T, primary, Read, Liam, additional, Waddington, Oliver, additional, Hamilton, Fergus W, additional, Patole, Sonia, additional, Hughes, Jessica, additional, Milne, Alice, additional, Noel, Alan, additional, Bayliss, Mark, additional, Maskell, Nick A, additional, and MacGowan, Alasdair, additional

Published
2023
Full Text
View/download PDF

21. One- and two-stage surgical revision of peri-prosthetic joint infection of the hip: a pooled individual participant data analysis of 44 cohort studies

Author

Kunutsor, Setor K., Whitehouse, Michael R., Blom, Ashley W., Board, Tim, Kay, Peter, Wroblewski, B. Mike, Zeller, Valérie, Chen, Szu-Yuan, Hsieh, Pang-Hsin, Masri, Bassam A., Herman, Amir, Jenny, Jean-Yves, Schwarzkopf, Ran, Whittaker, John-Paul, Burston, Ben, Huang, Ronald, Restrepo, Camilo, Parvizi, Javad, Rudelli, Sergio, Honda, Emerson, Uip, David E., Bori, Guillem, Muñoz-Mahamud, Ernesto, Darley, Elizabeth, Ribera, Alba, Cañas, Elena, Cabo, Javier, Cordero-Ampuero, José, Redó, Maria Luisa Sorlí, Strange, Simon, Lenguerrand, Erik, Gooberman-Hill, Rachael, Webb, Jason, MacGowan, Alasdair, Dieppe, Paul, Wilson, Matthew, and Beswick, Andrew D.

Published
2018

30. Predictive factors for multidrug-resistant gram-negative bacteria among hospitalised patients with complicated urinary tract infections

Author

Gomila, Aina, Shaw, Evelyn, Carratalà, Jordi, Leibovici, Leonard, Tebé, Cristian, Wiegand, Irith, Vallejo-Torres, Laura, Vigo, Joan M., Morris, Stephen, Stoddart, Margaret, Grier, Sally, Vank, Christiane, Cuperus, Nienke, Van den Heuvel, Leonard, Eliakim-Raz, Noa, Vuong, Cuong, MacGowan, Alasdair, Addy, Ibironke, and Pujol, Miquel

Published
2018
Full Text
View/download PDF

34. Additional file 1 of Predictive factors for multidrug-resistant gram-negative bacteria among hospitalised patients with complicated urinary tract infections

Author

Gomila, Aina, Shaw, Evelyn, Carratalà, Jordi, Leibovici, Leonard, Tebé, Cristian, Wiegand, Irith, Vallejo-Torres, Laura, Vigo, Joan M., Morris, Stephen, Stoddart, Margaret, Grier, Sally, Vank, Christiane, Cuperus, Nienke, Van den Heuvel, Leonard, Eliakim-Raz, Noa, Vuong, Cuong, MacGowan, Alasdair, Addy, Ibironke, and Pujol, Miquel

Abstract

Supplementary material. (DOCX 24 kb)

Published
2023
Full Text
View/download PDF

35. Exploring Cluster-Dependent Antibacterial Activities and Resistance Pathways of NOSO-502 and Colistin against Enterobacter cloacae Complex Species

Author

Pantel, Lucile, primary, Guérin, François, additional, Serri, Marine, additional, Gravey, François, additional, Houard, Jessica, additional, Maurent, Kelly, additional, Attwood, Marie, additional, Noel, Alan, additional, MacGowan, Alasdair, additional, Racine, Emilie, additional, Cattoir, Vincent, additional, and Gualtieri, Maxime, additional

Published
2022
Full Text
View/download PDF

37. Infection after total joint replacement of the hip and knee: research programme including the INFORM RCT

Author

Blom, Ashley W, primary, Beswick, Andrew D, additional, Burston, Amanda, additional, Carroll, Fran E, additional, Garfield, Kirsty, additional, Gooberman-Hill, Rachael, additional, Harris, Shaun, additional, Kunutsor, Setor K, additional, Lane, Athene, additional, Lenguerrand, Erik, additional, MacGowan, Alasdair, additional, Mallon, Charlotte, additional, Moore, Andrew J, additional, Noble, Sian, additional, Palmer, Cecily K, additional, Rolfson, Ola, additional, Strange, Simon, additional, and Whitehouse, Michael R, additional

Published
2022
Full Text
View/download PDF

38. Clinical and cost effectiveness of single stage compared with two stage revision for hip prosthetic joint infection (INFORM): pragmatic, parallel group, open label, randomised controlled trial

Author

Blom, Ashley W, primary, Lenguerrand, Erik, additional, Strange, Simon, additional, Noble, Sian M, additional, Beswick, Andrew D, additional, Burston, Amanda, additional, Garfield, Kirsty, additional, Gooberman-Hill, Rachael, additional, Harris, Shaun R S, additional, Kunutsor, Setor K, additional, Lane, J Athene, additional, MacGowan, Alasdair, additional, Mehendale, Sanchit, additional, Moore, Andrew J, additional, Rolfson, Ola, additional, Webb, Jason C J, additional, Wilson, Matthew, additional, and Whitehouse, Michael R, additional

Published
2022
Full Text
View/download PDF

41. Therapeutic potential of IL6R blockade for the treatment of sepsis and sepsis-related death: Findings from a Mendelian randomisation study

Author

Hamilton, Fergus, primary, Thomas, Matt, additional, Arnold, David, additional, Palmer, Tom, additional, Moran, Ed, additional, Mentzer, Alexander J, additional, Maskell, Nick, additional, Baillie, Kenneth, additional, Summers, Charlotte, additional, Hingorani, Aroon, additional, MacGowan, Alasdair, additional, Khandakar, Golam M, additional, Mitchell, Ruth, additional, Smith, George Davey, additional, Ghazal, Peter, additional, and Timpson, Nicholas J, additional

Published
2022
Full Text
View/download PDF

45. Duration of Treatment for Pseudomonas aeruginosa Bacteremia: a Retrospective Study

Author

Yahav, Dafna [0000-0003-3181-9791], Babich, Tanya, Naucler, Pontus, Valik, John Karlsson, Giske, Christian G., Benito, Natividad, Cardona, Rubén, Rivera, Alba, Pulcini, Céline, Fattah, Manal Abdel, Haquin, Justine, Macgowan, Alasdair, Grier, Sally, Chazan, Bibiana, Yanovskay, Anna, Ami, Ronen Ben, Landes, Michal, Nesher, Lior, Zaidman-Shimshovitz, Adi, McCarthy, Kate, Paterson, David L., Tacconelli, Evelina, Buhl, Michael, Mauer, Susanna, Rodríguez-Baño, Jesús, Cueto, Marina de, Oliver, Antonio, Ruiz de Gopegui Bordes, Enrique, Cano, Ángela, Machuca, Isabel, Gozalo-Margüello, Mónica, Martínez-Martínez, Luis, González-Barbera, Eva M., Gómez Alfaro, Iris, Salavert, Miguel, Beovic, Bojana, Saje, Andreja, Mueller-Premru, Manica, Pagani, Leonardo, Vitrat, Virginie, Kofteridis, Diamantis, Zacharioudaki, Maria, Maraki, Sofia, Weissman, Yulia, Paul, Mical, Dickstein, Yaakov, Leibovici, Leonard, Yahav, Dafna, Yahav, Dafna [0000-0003-3181-9791], Babich, Tanya, Naucler, Pontus, Valik, John Karlsson, Giske, Christian G., Benito, Natividad, Cardona, Rubén, Rivera, Alba, Pulcini, Céline, Fattah, Manal Abdel, Haquin, Justine, Macgowan, Alasdair, Grier, Sally, Chazan, Bibiana, Yanovskay, Anna, Ami, Ronen Ben, Landes, Michal, Nesher, Lior, Zaidman-Shimshovitz, Adi, McCarthy, Kate, Paterson, David L., Tacconelli, Evelina, Buhl, Michael, Mauer, Susanna, Rodríguez-Baño, Jesús, Cueto, Marina de, Oliver, Antonio, Ruiz de Gopegui Bordes, Enrique, Cano, Ángela, Machuca, Isabel, Gozalo-Margüello, Mónica, Martínez-Martínez, Luis, González-Barbera, Eva M., Gómez Alfaro, Iris, Salavert, Miguel, Beovic, Bojana, Saje, Andreja, Mueller-Premru, Manica, Pagani, Leonardo, Vitrat, Virginie, Kofteridis, Diamantis, Zacharioudaki, Maria, Maraki, Sofia, Weissman, Yulia, Paul, Mical, Dickstein, Yaakov, Leibovici, Leonard, and Yahav, Dafna

Abstract

[Introduction] There is no consensus regarding optimal duration of antibiotic therapy for Pseudomonas aeruginosa bacteremia. We aimed to evaluate the impact of short antibiotic course., [Methods] We present a retrospective multicenter study including patients with P. aeruginosa bacteremia during 2009–2015. We evaluated outcomes of patients treated with short (6–10 days) versus long (11–15 days) antibiotic courses. The primary outcome was a composite of 30-day mortality or bacteremia recurrence and/or persistence. Univariate and inverse probability treatment-weighted (IPTW) adjusted multivariate analysis for the primary outcome was performed. To avoid immortal time bias, the landmark method was used., [Results] We included 657 patients; 273 received a short antibiotic course and 384 a long course. There was no significant difference in baseline characteristics of patients. The composite primary outcome occurred in 61/384 patients in the long-treatment group (16%) versus 32/273 in the short-treatment group (12%) (p = 0.131). Mortality accounted for 41/384 (11%) versus 25/273 (9%) of cases, respectively. Length of hospital stay was significantly shorter in the short group [median 13 days, interquartile range (IQR) 9–21 days, versus median 15 days, IQR 11–26 days, p = 0.002]. Ten patients in the long group discontinued antibiotic therapy owing to adverse events, compared with none in the short group. On univariate and multivariate analyses, duration of therapy was not associated with the primary outcome., [Conclusions] In this retrospective study, 6–10 days of antibiotic course for P. aeruginosa bacteremia were as effective as longer courses in terms of survival and recurrence. Shorter therapy was associated with reduced length of stay and less drug discontinuation.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results